Cargando…
Gemcitabine plus vinorelbine in elderly or unfit patients with non-small cell lung cancer
Cisplatin-based combinations are efficacious in increasing the overall survival of patients with non-small cell lung cancer (NSCLC), but their toxicity makes them unsuitable for elderly and unfit patients. The primary objective of this non-randomized phase II study was to evaluate the feasibility an...
Autores principales: | Beretta, G D, Michetti, G, Belometti, M O, Gritti, G, Quadri, A, Poletti, P, Labianca, R |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2000
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363520/ https://www.ncbi.nlm.nih.gov/pubmed/10944594 http://dx.doi.org/10.1054/bjoc.2000.1304 |
Ejemplares similares
-
Gemcitabine with either paclitaxel or vinorelbine vs paclitaxel or gemcitabine alone for elderly or unfit advanced non-small-cell lung cancer patients
por: Comella, P, et al.
Publicado: (2004) -
Gemcitabine plus vinorelbine in advanced non-small cell lung cancer: a phase II study of three different doses
por: Gridelli, C, et al.
Publicado: (2000) -
Randomised phase II trial of gemcitabine plus vinorelbine vs gemcitabine plus cisplatin vs gemcitabine plus capecitabine in patients with pretreated metastatic breast cancer
por: Stemmler, H J, et al.
Publicado: (2011) -
Comparison of Vinorelbine-Cisplatin with Gemcitabine-Cisplatin in Patients with Advanced Non-Small Cell Lung Cancer
por: Ozkaya, Sevket, et al.
Publicado: (2008) -
Long-term survival rates of patients with stage IIIB and IV non-small cell lung cancer treated with cisplatin plus vinorelbine or gemcitabine
por: OZKAYA, SEVKET, et al.
Publicado: (2012)